Chongqing Zhifei Bio Products (300122)
Shenzhen Stock Exchange · China · prices in CNY · close of 21 Oct 2026
Key indicators
| Last close | CNY 12.74 |
|---|---|
| 52-week range | 11.07 – 22.18 |
| Return, 1 month / 3 months | +1.8% / −1.7% |
| Return, 1 year / 3 years | −38.7% / −70.1% |
| Trend | Below its 200-day average |
| RSI (14) | 46 |
| Volatility (1 year) | 44.5% |
| Worst drawdown (1 year) | -47.8% |
| Average daily value traded | 475.27M CNY |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Chongqing Zhifei Biological Products is a Chinese biopharmaceutical company based in Chongqing that focuses on vaccines. It develops and produces its own vaccine products and also acts as an agent for vaccines made by other manufacturers, distributing them across China. The company serves public health and immunisation markets through a network of vaccination clinics and partners, and it carries out research and development work on new vaccines for infectious diseases.
The shares are listed on the Shenzhen Stock Exchange in China under the code 300122, and the price on this page is in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Chongqing Zhifei Bio Products (300122) trades on the Shenzhen Stock Exchange in China. It last closed at CNY 12.74 on 21 October 2026.
Its price-based Market X-Ray is 50 out of 100 (a fair price profile), ranking 1,424 of 2,821 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 38.7% and over the last three months it fell 1.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shenzhen Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 45 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -13.7% | ||
| From 52-week high | -41.5% | ||
| Momentum | 35 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -1.7% | ||
| 6-month return | -19.8% | ||
| 12-month return, skipping the last month | -39.8% | ||
| Stability (higher is calmer) | 51 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 44.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -47.8% | ||
| Liquidity | 84 · Strong | Trades actively. | |
| Average daily value traded | 475.27M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 3 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −0.1% |
|---|---|
| 1 month | +1.8% |
| 3 months | −1.7% |
| 6 months | −19.8% |
| 1 year | −38.7% |
| 3 years | −70.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 13.17 / 14.77 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.50 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 25 Dec 2024 | CNY 0.2000 |
| 8 Aug 2024 | CNY 0.8000 |
| 16 Jun 2023 | CNY 0.7700 |
| 15 Jul 2022 | CNY 0.6000 |
| 6 Aug 2021 | CNY 0.5000 |
| 12 Aug 2020 | CNY 0.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shenzhen Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.